Dashboard
1
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of 6.25% and Operating profit at 10.50% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 16.05% signifying low profitability per unit of shareholders funds
2
Poor long term growth as Net Sales has grown by an annual rate of 6.25% and Operating profit at 10.50% over the last 5 years
3
With ROE of 12.74%, it has a attractive valuation with a 1.23 Price to Book Value
4
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
CNY 4,157 Million (Mid Cap)
10.00
NA
4.66%
0.85
12.04%
0.87
Revenue and Profits:
Net Sales:
8,595 Million
(Quarterly Results - Mar 2026)
Net Profit:
103 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-12.14%
0%
-12.14%
6 Months
-6.91%
0%
-6.91%
1 Year
2.08%
0%
2.08%
2 Years
-3.49%
0%
-3.49%
3 Years
-17.2%
0%
-17.2%
4 Years
-9.56%
0%
-9.56%
5 Years
-22.22%
0%
-22.22%
Zhejiang Int'l Group Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
6.25%
EBIT Growth (5y)
10.50%
EBIT to Interest (avg)
4.91
Debt to EBITDA (avg)
4.05
Net Debt to Equity (avg)
0.97
Sales to Capital Employed (avg)
3.50
Tax Ratio
24.16%
Dividend Payout Ratio
37.57%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.23%
ROE (avg)
16.05%
Valuation key factors
Factor
Value
P/E Ratio
10
Industry P/E
Price to Book Value
1.23
EV to EBIT
10.48
EV to EBITDA
8.53
EV to Capital Employed
1.13
EV to Sales
0.29
PEG Ratio
1.03
Dividend Yield
3.35%
ROCE (Latest)
10.78%
ROE (Latest)
12.74%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bullish
Dow Theory
No Trend
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
8,595.00
8,716.60
-1.40%
Operating Profit (PBDIT) excl Other Income
151.40
374.20
-59.54%
Interest
26.70
55.50
-51.89%
Exceptional Items
0.00
0.00
Consolidate Net Profit
103.20
223.10
-53.74%
Operating Profit Margin (Excl OI)
17.60%
35.90%
-1.83%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is -1.40% vs 4.59% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is -53.74% vs 140.93% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
33,634.70
33,312.90
0.97%
Operating Profit (PBDIT) excl Other Income
1,182.30
1,124.60
5.13%
Interest
168.00
155.30
8.18%
Exceptional Items
0.50
0.10
400.00%
Consolidate Net Profit
604.00
611.90
-1.29%
Operating Profit Margin (Excl OI)
28.20%
27.70%
0.05%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.97% vs 4.16% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -1.29% vs 3.94% in Dec 2024
About Zhejiang Int'l Group Co., Ltd. 
Zhejiang Int'l Group Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






